Effectiveness and Safety of Toripalimab Combination Therapies for Patients With Chemo-Resistant Choriocarcinoma.

Liu, Xiaomei; Li, Xiuqin; Qu, Hui; Zhang, Shiyue; Zhang, Ruizhe; Du, Zhenhua

Liu, Xiaomei; Li, Xiuqin; Qu, Hui; Zhang, Shiyue; Zhang, Ruizhe; Du, Zhenhua.

Afiliación

Liu X; Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.
Li X; Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.
Qu H; Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.
Zhang S; Shanghai Junshi Biosciences Co, Ltd., Shanghai, China.
Zhang R; Shanghai Junshi Biosciences Co, Ltd., Shanghai, China.
Du Z; Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.

Front Oncol ; 12: 815917, 2022.

Article en En | MEDLINE | ID: mdl-35494052

Palabras clave

PD-1 checkpoint inhibitors; chemo-resistant; choriocarcinoma; effectiveness and safety; toripalimab

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google